| Ye, Dingwei |
ACCRUE, NCT04490993: Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients |
|
|
| Active, not recruiting | 3 | 359 | RoW | APL-1202 in combination with Epirubicin, Placebo in combination with Epirubicin | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 05/22 | 05/22 | | |
NCT04859751: Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 3 | 53 | RoW | VB4-845 Injection | Qilu Pharmaceutical Co., Ltd. | Non-Muscle Invasive Bladder Cancer | 06/22 | 12/23 | | |
CHART, NCT03520478: A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer |
|
|
| Active, not recruiting | 3 | 654 | Europe, RoW | SHR3680, Bicalutamide | Jiangsu HengRui Medicine Co., Ltd. | Prostate Cancer, Hormone-Dependent Prostate Cancer | 04/23 | 04/25 | | |
RATIONALE-310, NCT03967977: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma |
|
|
| Recruiting | 3 | 420 | RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin | BeiGene | Urothelial Carcinoma | 06/27 | 06/27 | | |
NCT06592326: 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Recruiting | 3 | 460 | RoW | 9MW2821, Toripalimab, Toripalimab injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin/Carboplatin, Cisplatin for injection/Carboplatin Injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Urothelial Carcinoma | 09/27 | 12/28 | | |
Ascertain, NCT04736394: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients |
|
|
| Recruiting | 3 | 800 | RoW | APL-1202, Epirubicin Hydrochloride | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Non-muscle Invasive Bladder Cancer | 03/25 | 12/25 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT05009290: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy |
|
|
| Recruiting | 3 | 1256 | RoW | SHR3680, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 10/27 | 10/31 | | |
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2/3 | 265 | RoW | fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013 | Hutchmed | Advanced Renal Cell Carcinoma | 01/25 | 03/25 | | |
NCT04718584: the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors |
|
|
| Recruiting | 2 | 127 | RoW | Human Anti-PD-L1 Monoclonal Antibody Injection (LDP), LDP | Dragonboat Biopharmaceutical Company Limited, Fudan University | Bladder Cancer, Renal Carcinoma, Advanced Penile Carcinoma | 11/22 | 11/23 | | |
| Recruiting | 2 | 265 | RoW | SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule | Jiangsu HengRui Medicine Co., Ltd. | Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer | 12/22 | 12/22 | | |
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 110 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Bladder Cancer | 12/22 | 12/23 | | |
NCT06222125: A Study of HB0025 Injection in Patients With Advanced Renal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | HB0025, Recombinant humanized anti-programmed cell death-ligand 1（Anti-PD-L1） monoclonal antibody-VEGFR1 fusion protein | Huabo Biopharm Co., Ltd. | Renal Cancer | 01/25 | 12/25 | | |
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Urothelial Carcinoma | 05/26 | 05/26 | | |
AK104-213, NCT05256472: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | AK104, axitinib | Akeso | Renal Cell Carcinoma, First-line Treatment | 07/24 | 12/25 | | |
HS-20093-202, NCT06001255: ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors |
|
|
| Recruiting | 2 | 120 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Metastasis Castration Resistant Prostate Cancer(mCRPC) | 12/24 | 12/25 | | |
NCT05785039: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors |
|
|
| Recruiting | 2 | 76 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Urinary System Tumor, Solid Tumor | 04/25 | 04/25 | | |
NCT05965856: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Urothelial Carcinoma, Solid Tumor | 12/25 | 12/25 | | |
NCT05775874: A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC |
|
|
| Recruiting | 2 | 80 | RoW | AZD4547, FGFR1/2/3/4 inhibitor, Tislelizumab, PD1 inhibitor | Abbisko Therapeutics Co, Ltd | Urothelial Carcinoma | 09/25 | 12/25 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
NCT05086666: A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 |
|
|
| Recruiting | 1b/2 | 108 | RoW | AZD4547, ABSK091 | Abbisko Therapeutics Co, Ltd | Urothelial Carcinoma | 08/23 | 05/24 | | |
NCT06732531: Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 48 | RoW | BH011, Docetaxel | Zhuhai Beihai Biotech Co., Ltd | Bladder Cancer, Non Muscle Invasive | 12/25 | 12/25 | | |
ANTICIPATE, NCT04813107: A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 79 | US, RoW | APL-1202 in combination with tislelizumab, Tislelizumab alone | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Muscle Invasive Bladder Cancer | 11/23 | 03/24 | | |
NCT06139575: Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer |
|
|
| Recruiting | 1/2 | 90 | RoW | Lutetium Lu 177 JH020002 Injection | Bivision Pharmaceuticals, Inc. | Prostate Cancer | 05/26 | 07/27 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06081686: Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer |
|
|
| Recruiting | 1/2 | 32 | RoW | Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection | Sinotau Pharmaceutical Group | Prostate Cancer | 12/25 | 12/25 | | |
| Completed | 1 | 12 | RoW | BH002 | Zhuhai Beihai Biotech Co., Ltd | Solid Tumours | 03/23 | 03/23 | | |
| Recruiting | 1 | 120 | RoW | TQB3720 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 05/23 | 05/23 | | |
NCT05099536: 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors |
|
|
| Withdrawn | 1 | 93 | RoW | 3D011-08 | 3D Medicines (Beijing) Co., Ltd. | Solid Tumor, Adult | 09/23 | 09/23 | | |
NCT06186414: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC |
|
|
| Recruiting | 1 | 152 | RoW | SIM0237, SIM0237 and BCG | Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd. | Non-Muscle-Invasive Bladder Cancer (NMIBC) | 01/27 | 12/30 | | |
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 66 | US, RoW | INV-9956 | Shenzhen Ionova Life Sciences Co., Ltd. | Advanced Metastatic Castration Resistant Prostate Cancer | 04/26 | 03/27 | | |
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors |
|
|
| Not yet recruiting | 1 | 87 | RoW | BPI-452080 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 03/25 | 10/25 | | |
NCT06094777: A Study of HY-0102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | HY-0102 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
